Open Orphan

9 results

The fundraising has been underwritten by Raglan Capital, an entity controlled by executive chairman Cathal Friel.

Dublin-listed pharma services company Open Orphan raised £5.3 million though a share placing on Friday. Open Orphan, a European-focussed, rare and or(...)

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, informed investors of the deal.

Dublin-listed pharma services company Open Orphan has signed a new three-year contract with a German pharmaceutical company, which it said will guaran(...)

Balance for Better Business co-chairs Brid Horan and Gary Kennedy. Photograph: Leah Farrell/RollingNews.ie

A “serious gender imbalance” persists at the top level of businesses in Ireland, with 13 companies trading on the Euronext Dublin retaining all-male b(...)

NYSE traders work on the floor  at the start of the trading day,  December 9th.  Photograph: Epa/Justin Lane

A slump in Irish-founded Tullow Oil’s shares and weak data from China left European stocks trailing on Monday. DUBLIN Food group Kerry closed on Mon(...)

Integumen offers a range of products in the skin science, oral health and woundcare sector. Photograph: iStock

Dalkey-based Integumen is to raise £1.4 million (€1.66 million) through a share placing and subscription to provide working capital as it looks to boo(...)

Open Orphan is the result of Cathal  Friel reversing his pharma services business of the same name into Dublin-listed drug clinical trials manager Venn Life Sciences earlier this year

Dublin-listed pharma services company Open Orphan said on Monday it has agreed to merge with UK-based Hvivo in a £30 million (€35.7m) tie-up that clas(...)

 Empiric Logic CEO Gareth O’Sullivan and senior data scientist Shubham Gorawara at NovaUCD. Photograph: Paul Sharp/Sharppix

It can take up to 15 years and about $2.5 billion to develop a new drug treatment, so anything with the potential to shorten this cycle is going to pi(...)

Pharma services business Open Orphan said admission and dealings in its ordinary shares of 0.1 pence each on AIM and Euronext Growth Dublin would commence at 8am on Friday under the ticker ORPH

Pharma services business Open Orphan, formerly known as Venn Life Sciences, has resumed trading on the stock exchanges in Dublin and London following (...)

Cathal Friel, who has taken over as chief executive at Venn Life Sciences following an agreement to merge it with his company, Open Orphan. Photograph: Fennell Photography

Leading corporate figure Cathal Friel is behind the proposed reverse takeover of listed clinical trials group Venn Life Sciences by pharma services bu(...)